Opinion|Videos|July 29, 2024
ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the emerging data presented at ASCO 2024 on the phase 1 study of IMC-F106C (brenetafusp), a PRAME x CD3 ImmTAC bispecific protein in post-checkpoint cutaneous melanoma. (
Abstract )
1. What was the objective of this study?
2. How was this study designed/what methodology was used?
3. What results were presented?
i. Patient population: N=46
A. Prior therapy: 100% anti-PD1, 88% anti-CTLA4, 25% BRAF/MEK inhibitors
ii. Primary objectives:
A. Safety
B. Selection of recommended dose
iii. Secondary objectives:
A. Efficacy
B. ctDNA response
- Please provide your key takeaways from this study. How might a PRAME x CD3 bispecific product impact the management of melanoma in the future?
Advertisement
Related to this article
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.
Advertisement
Advertisement
Trending on AJMC
1
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
2
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
3
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
4
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
5